Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
eligard 45 mg
recordati industria chimica e farmaceutica s.p.a., taliansko - leuprorelín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
dulcolax čapíky
opella healthcare slovakia s.r.o., slovensko - bisakodyl - 61 - laxantia
Európska únia -
slovenčina -
EMA (European Medicines Agency)
ultomiris
alexion europe sas - ravulizumab - hemoglobinúria, paroxysmálna - selektívne imunosupresíva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
reagencie ivd adaltis ostatné - špecifické proteíny
adaltis italia spa via cristoni, 12 - casalecchio di reno 40033 bologna taliansko -
Slovensko -
slovenčina -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
nicorette icemint gum 2 mg
mcneil ab, Švédsko - nikotín - 87 - varia i
Európska únia -
slovenčina -
EMA (European Medicines Agency)
human igg1 monoclonal antibody specific for human interleukin-1 alpha xbiotech
xbiotech germany gmbh - ľudská igg1 monoklonálna protilátka špecifická pre ľudský interleukín-1a - kolorektálne novotvary - antineoplastické činidlá - liečba metastatickým kolorektálnym.
Európska únia -
slovenčina -
EMA (European Medicines Agency)
evenity
ucb pharma s.a. - romosozumab - osteoporóza - lieky na liečbu chorôb kostí - evenity je indikovaný v liečbe ťažkej osteoporózy u postmenopauzálnych žien s vysokým rizikom zlomeniny.
Európska únia -
slovenčina -
EMA (European Medicines Agency)
piqray
novartis europharm limited - alpelisib - neoplazmy prsníkov - antineoplastické činidlá - piqray je indikovaný v kombinácii s fulvestrant pri liečbe postmenopauzálnych žien a mužov, s hormonálny receptor (hr)-pozitívnu, ľudskej pokožky growth factor receptor 2 (her2)-negatívne, lokálne pokročilého alebo metastatického karcinómu prsníka s pik3ca mutácie po progresii ochorenia týchto žliaz s vnútornou sekréciou, terapia ako monotherapy (pozri časť 5.
Európska únia -
slovenčina -
EMA (European Medicines Agency)
minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastické činidlá - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).